Wang Yaohui, Jiang Yinan, Zhou Jinxue, Song Wuhui, Li Jing, Wang Mingli, Chen Jiuge, Xu Rui, Zhang Jingjing, Ma Fanni, Chen Youhai H, Ma Yuanfang
Henan Key Laboratory of Engineering Antibody Medicine, Medical College of Henan University, Kaifeng, Henan, 475004, China.
College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China.
Tumour Biol. 2016 Nov;37(11):15265-15274. doi: 10.1007/s13277-016-5409-z. Epub 2016 Sep 30.
Infection of hepatitis C virus (HCV) is associated with primary hepatocellular carcinoma (HCC). However, its underlying molecular mechanisms remain enigmatic. Tumor necrosis factor-α-induced protein 8-like 2 (TIPE2), a new negative regulator of immunity, plays significant roles in modulating inflammation and tumorigenesis. We hypothesized that TIPE2 might be involved in the development of HCV-induced HCC. To test this hypothesis, the expression of TIPE2 was determined by Western blot in the tumor and pericarcinomatous tissues collected from ten HCV-positive HCC patients; the interaction between TIPE2 and HCV-encoded non-structural proteins was analyzed by immunoprecipitation and immunofluorescence assays, and tumorigenesis and its mechanisms were studied in cell models and nude mice. Our results demonstrated that the expression of TIPE2 was significantly reduced in HCC tissues compared to that in the paracarcinoma tissues. HCV-encoded non-structural protein NS5A could specifically interact with TIPE2 and induce its degradation. Downregulation of TIPE2 by shRNA in cell lines increased genomic DNA damage and promoted cell colony formation in vitro and tumorigenesis in nude mice. In contrast, overexpression of TIPE2 had an opposite effect. Downregulation of TIPE2 by NS5A is associated with genomic DNA instability and HCV-induced HCC development. Thus, TIPE2 may be a new therapeutic target for the treatment of HCV-associated HCC.
丙型肝炎病毒(HCV)感染与原发性肝细胞癌(HCC)相关。然而,其潜在的分子机制仍不清楚。肿瘤坏死因子-α诱导蛋白8样2(TIPE2)是一种新的免疫负调节因子,在调节炎症和肿瘤发生中起重要作用。我们推测TIPE2可能参与了HCV诱导的HCC的发生发展。为验证这一假设,采用蛋白质免疫印迹法检测了10例HCV阳性HCC患者肿瘤组织和癌旁组织中TIPE2的表达;通过免疫沉淀和免疫荧光分析TIPE2与HCV编码的非结构蛋白之间的相互作用,并在细胞模型和裸鼠中研究肿瘤发生及其机制。我们的结果表明,与癌旁组织相比,HCC组织中TIPE2的表达显著降低。HCV编码的非结构蛋白NS5A可与TIPE2特异性相互作用并诱导其降解。在细胞系中用短发夹RNA下调TIPE2可增加基因组DNA损伤,并促进体外细胞集落形成和裸鼠肿瘤发生。相反,TIPE2过表达则产生相反的效果。NS5A下调TIPE2与基因组DNA不稳定及HCV诱导的HCC发生发展有关。因此,TIPE2可能是治疗HCV相关HCC的一个新的治疗靶点。